Natixis Acquires 14,705 Shares of Amgen Inc. (NASDAQ:AMGN)

Natixis raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,431 shares of the medical research company’s stock after buying an additional 14,705 shares during the period. Natixis’ holdings in Amgen were worth $39,105,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. FIL Ltd boosted its stake in shares of Amgen by 129.0% during the 1st quarter. FIL Ltd now owns 1,954,019 shares of the medical research company’s stock worth $486,180,000 after buying an additional 1,100,742 shares during the last quarter. Franklin Resources Inc. boosted its stake in Amgen by 59.0% in the 1st quarter. Franklin Resources Inc. now owns 2,954,867 shares of the medical research company’s stock valued at $735,201,000 after purchasing an additional 1,096,236 shares during the period. Bank of Montreal Can boosted its stake in Amgen by 84.4% in the 2nd quarter. Bank of Montreal Can now owns 2,358,762 shares of the medical research company’s stock valued at $601,863,000 after purchasing an additional 1,079,366 shares during the period. Liberty Wealth Management LLC boosted its stake in Amgen by 25,684.8% in the 2nd quarter. Liberty Wealth Management LLC now owns 478,823 shares of the medical research company’s stock valued at $1,950,000 after purchasing an additional 476,966 shares during the period. Finally, Mn Services Vermogensbeheer B.V. bought a new stake in Amgen in the 2nd quarter valued at $87,044,000. 74.73% of the stock is owned by institutional investors.

Shares of Amgen stock traded up $3.72 on Thursday, hitting $205.61. 4,875 shares of the company’s stock traded hands, compared to its average volume of 2,603,943. Amgen Inc. has a one year low of $200.47 and a one year high of $276.69. The company has a fifty day moving average of $219.46 and a two-hundred day moving average of $236.52. The company has a debt-to-equity ratio of 3.45, a current ratio of 1.31 and a quick ratio of 1.03. The company has a market capitalization of $116.76 billion, a price-to-earnings ratio of 20.71, a price-to-earnings-growth ratio of 1.55 and a beta of 0.68.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Monday, August 2nd. The medical research company reported $4.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.09 by $0.29. Amgen had a net margin of 22.55% and a return on equity of 99.85%. The firm had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $6.43 billion. Equities research analysts anticipate that Amgen Inc. will post 16.41 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 8th. Stockholders of record on Tuesday, August 17th were paid a $1.76 dividend. The ex-dividend date of this dividend was Monday, August 16th. This represents a $7.04 annualized dividend and a dividend yield of 3.42%. Amgen’s payout ratio is 42.41%.

Several analysts recently issued reports on AMGN shares. William Blair restated a “hold” rating on shares of Amgen in a research note on Friday, September 17th. Robert W. Baird restated a “sell” rating on shares of Amgen in a research report on Thursday, August 5th. Daiwa Capital Markets downgraded Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 price objective for the company. in a research report on Thursday, September 23rd. SVB Leerink began coverage on Amgen in a research report on Sunday, September 19th. They set a “hold” rating for the company. Finally, Morgan Stanley dropped their price objective on Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $244.58.

Amgen Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Further Reading: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.